icon-folder.gif   Conference Reports for NATAP  
  10th International Congress on Drug Therapy in HIV Infection
November 7-11, 2010
Back grey_arrow_rt.gif
Pooled Week 48 safety and efficacy results from the ECHO and THRIVE Phase III trials comparing TMC278 vs efavirenz in treatment-naïve HIV-1-infected patients
  Reported by Jules Levin
Glasgow Nov 12 2010
C Cohen,1 JM Molina,2 P Cahn,3 B Clotet,4 J Fourie,5 B Grinsztejn,6 W Hao,7 M Johnson,8 K Supparatpinyo,9 H Crauwels,10 L Rimsky,10 S Vanveggel,10 P Williams,10 K Boven11 1Community Research Initiative of New England, Boston, MA, USA; 2Saint-Louis Hospital and University of Paris, Paris, France; 3Hospital Juan A Fernández and Fundacion Huesped, Buenos Aires, Argentina; 4Hospital Universitari Germans Trias i Pujol and irsiCaixa Foundation, UAB, Barcelona, Spain; 5Dr J Fourie Medical Centre, Dundee, KwaZulu Natal, South Africa; 6Instituto de Pesquisa Clínica Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil; 7Beijing You'an Hospital, Beijing, China; 8Royal Free Hospital, London, UK; 9Chiang Mai University, Chiang Mai, Thailand; 10Tibotec BVBA, Beerse, Belgium; 11Tibotec Inc., Titusville, NJ, USA